Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.21.2
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2021
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]            
Total revenue   $ 4,057   $ 2,939 $ 22,975 $ 27,446
Seagen            
Disaggregation of Revenue [Line Items]            
Total revenue   (280)   366 424 9,326
AstraZeneca            
Disaggregation of Revenue [Line Items]            
Total revenue $ 13,000 1,607 $ 13,000 2,182 18,309 7,227
Servier            
Disaggregation of Revenue [Line Items]            
Total revenue   1,867   391 3,379 10,893
Genentech            
Disaggregation of Revenue [Line Items]            
Total revenue   $ 863   $ 0 $ 863 $ 0